Skip to main content
padlock icon - secure page this page is secure

Open Access Targeting RSV with Vaccines and Small Molecule Drugs

Download Article:
(PDF 825.9 kb)
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antiviral; MedImmune; Palivizumab; antiviral drug; attachment glycoprotein; cystic fibrosis; fusion glycoprotein; influenza virus; malnutrition; palivizumab; premature birth; respiratory syncytial virus; therapeutic; vaccine

Document Type: Research Article

Publication date: April 1, 2012

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more